Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR EU) 2018
Authors: Simon O, Wilczynski O, Khalil J
Multiple Sclerosis (MS) is a neurodegenerative disease frequently causing walking impairment. Prolonged-release PR-fampridine (dalfampridine extended-release in US) is approved for the improvement of gait function in MS patients with walking disability (Expanded Disability Status Scale 4-7). Fampridine targets the underlying neurological causes of MS walking impairment through modification of neurotransmission in the CNS and can be used in patients with any subtype of MS. The study aims at observing how patients’ daily life evolved following the prescription of PR-fampridine.